Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-L1 Inhibitor Combined With Apatinib Maintenance in ES-SCLC
NCT06429696Phase 2Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jul 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in small cell lung cancer (SCLC), sponsored by Nanfang Hospital, Southern Medical University. Started Jul 2024; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06429696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06429696.